QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA)))) today announced the launch of the QIAstat-Dx Gastrointestinal Panel 2 in the United States. The launch comes after the recent clearance of the syndromic test for
GoGreen Investments Corporation (NYSE:GOGN) (the "Company" or "GoGreen") announced today that it has issued a promissory note in the principal amount of up to $2,760,000 (the "Extension